1803005-18-6
Chemical Structure
Tofacitinib hydrochloride
Synonym(s): Tasocitinib hydrochloride; CP-690550 hydrochloride
- CAS No.: 1803005-18-6
- Formula:C16H21ClN6O
- Molecular Weight:348.83
InChIKey: GAAYSQZMMCUMRF-YLAFAASESA-N
SMILES: CN([C@H]1CN(CC[C@H]1C)C(CC#N)=O)C2=C3C(NC=C3)=NC=N2.Cl
Biological Activity: Tofacitinib hydrochloride (Tasocitinib hydrochloride) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib hydrochloride blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib hydrochloride can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tofacitinib hydrochloride | Tofacitinib hydrochloride (Tasocitinib hydrochloride) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib hydrochloride blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib hydrochloride can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gao YN, et al. Tofacitinib prevents depressive-like behaviors through decreased hippocampal microgliosis and increased BDNF levels in both LPS-induced and CSDS-induced mice. Acta pharmacologica Sinica. 2025 Feb;46(2):353-365. [Content Brief]
- [2]. Sendo S, et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis research & therapy. 2019 Aug 06;21(1):184.
- [3]. Zhang X, et al. Tofacitinib reduces acute lung injury and improves survival in a rat model of sepsis by inhibiting the JAK-STAT/NF-κB pathway. Journal of inflammation (London, England). 2023 Feb 03;20(1):5.
- [4]. Wang W, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. Journal of scleroderma and related disorders. 2020 Feb;5(1):40-50.
- [5]. Wei X, et al. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis. Molecular pharmaceutics. 2018 Aug 06;15(8):3456-3467.
- [6]. Fleischmann R, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495-507.
- [7]. Sandborn WJ, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616-24.
- [8]. Furumoto Y, et al. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis & rheumatology (Hoboken, N.J.). 2017 Jan;69(1):148-160.
- [9]. Wang H, et al. The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice. Molecular medicine reports. 2019 Dec;20(6):4883-4892.
